This video provides a detailed financial analysis of the latest quarterly earnings reports for three distinct companies: MercadoLibre (MELI), Hims & Hers Health (HIMS), and Brookfield Asset Management (BAM).
For MercadoLibre, the analysis highlights strong top-line revenue and volume growth across its commerce and fintech segments. Despite a market sell-off due to compressed margins, the presenter argues that the company's strategic investments in areas like free shipping are successfully strengthening its competitive moat and accelerating user growth.
The review of Hims & Hers is more critical. While revenue grew year-over-year, it declined quarter-over-quarter due to the halt of commercial semaglutide compounding. The presenter raises several red flags, including decelerating subscriber growth, a potential decline in the non-GLP1 core business, and a perceived lack of management transparency. The analysis also questions the company's long-term competitive moat.
Finally, the video examines Brookfield Asset Management, praising it as a high-quality business executing well, with strong growth in fee-related earnings and significant new partnerships with major entities like Google. However, the presenter concludes that the stock's valuation has become too high, trading at over 40 times distributable earnings, and is therefore currently overpriced.
Earnings Analysis: MercadoLibre, HIMS, and Brookfield Asset Management
0:43 MercadoLibre (MELI) - Strong Growth Despite Market Sell-Off: MELI reported impressive Q2 results with net revenues of $6.8 billion (up 34% YoY) and total payment volume of $64.6 billion (up 39% YoY). The stock sold off because net income missed analyst expectations.
1:41 Strategic Investments Deepen Competitive Moat: The profit miss was driven by deliberate investments, including lowering the free shipping threshold in Brazil. The presenter views this positively, as it accelerated items-sold growth to 34% in Brazil and strengthened the company's long-term competitive advantage.
6:45 Fintech and Advertising Segments Accelerate: MELI’s fintech business is booming, with assets under management doubling year-over-year to $13.8 billion and its credit portfolio growing 91% to $9.3 billion. The advertising business also accelerated, growing 38% YoY after a partnership with Google Ad Manager.
15:13 Favorable Valuation Thesis: The presenter estimates MELI has a $5 billion annual free cash flow potential, putting its valuation at a fair 24 times FCF potential for a business with a strong moat growing over 30% annually.
17:11 Hims & Hers (HIMS) - Revenue Declines Quarter-Over-Quarter: HIMS reported Q2 revenue of $545 million (up 73% YoY) but saw a sequential decline from Q1. This was expected, as the company had to stop mass-compounding semaglutide after it was removed from the FDA shortage list.
20:01 Subscriber Growth Decelerates: A key concern is the significant deceleration in subscriber growth, which fell to just 3% in Q2. While partially attributable to offboarding semaglutide users, it is flagged as a key metric to watch.
24:28 Red Flag - Stagnant Guidance Despite Acquisition: HIMS did not raise its full-year 2025 revenue guidance, even after acquiring Zava Global, which is expected to add $50 million in revenue. This suggests potential weakness or deceleration in the core business.
29:33 Red Flag - Lack of Transparency and Weakening Core: The presenter criticizes management for not being transparent about the performance of the non-GLP1 "core" business, which he calculates also declined quarter-over-quarter. Management tends to focus on YoY growth, potentially obscuring this weakness.
37:37 Brookfield Asset Management (BAM) - A High-Quality Business: BAM reported a solid quarter with fee-related earnings up 16% and distributable earnings up 12%. The company has been active, monetizing over $55 billion in assets YTD and signing major partnerships with Google and the country of Sweden.
42:30 Overvaluation Concerns: Despite being a fantastic business, the presenter argues that BAM is overvalued. The stock is trading at over 40 times trailing distributable earnings, a price he considers too expensive. He sold his position to invest in the parent company, Brookfield Corporation (BN), which he sees as a better value.